UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 94

Sortiert nach

Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry

Clinical rheumatology, 2017-04, Vol.36 (4), p.753-761

2017

Link zum Volltext

Verfügbarkeit prüfen

Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis

Frontiers in pharmacology, 2022-08, Vol.13, p.887462-887462

2022

Link zum Volltext

Verfügbarkeit prüfen

Two‐year persistence of golimumab as second‐line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real‐life data from the LORHEN registry

International journal of rheumatic diseases, 2018-02, Vol.21 (2), p.422-430

2018

Link zum Volltext

Verfügbarkeit prüfen

Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry

Frontiers in medicine, 2024, Vol.11, p.1349533-1349533

2024

Link zum Volltext

Verfügbarkeit prüfen

Analisi di budget impact del biosimilare di etanercept: lo scenario italiano

Global & regional health technology assessment (Online), 2018-01, Vol.2018, p.228424031876680

2018

Link zum Volltext

Verfügbarkeit prüfen

Factors predicting early discontinuation of methotrexate as a first-line treatment for rheumatoid arthritis in Italy: Results from the GISEA registry

Indian journal of rheumatology, 2019-10, Vol.14 (4), p.271-276

2019

Link zum Volltext

Verfügbarkeit prüfen

COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study

The Lancet. Rheumatology, 2020-09, Vol.2 (9), p.e549-e556

2020

Link zum Volltext

Verfügbarkeit prüfen

Obesity and reduction of the response rate to anti–tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine

Arthritis care & research (2010), 2013-01, Vol.65 (1), p.94-100

2013

Link zum Volltext

Verfügbarkeit prüfen

Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study

Rheumatology (Oxford, England), 2015-05, Vol.54 (5), p.792-797

2015

Link zum Volltext

Verfügbarkeit prüfen

TNF-α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice

Annals of the New York Academy of Sciences, 2009-09, Vol.1173 (1), p.837-846

2009

Link zum Volltext

Verfügbarkeit prüfen

The measurement of fibromyalgia severity: converting scores between the FIQR, the PSD and the FASmod

Clinical and experimental rheumatology, 2023-06, Vol.41 (6), p.1225

2023

Link zum Volltext

Verfügbarkeit prüfen

Impact of one-year treatment with biotechnological drugs on work ability in patients with rheumatoid arthritis in Italy: a prospective real-life study

Clinical and experimental rheumatology, 2021-03, Vol.39 (2), p.263

2021

Link zum Volltext

Verfügbarkeit prüfen

Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors

Journal of rheumatology, 2012-06, Vol.39 (6), p.1179

2012

Link zum Volltext

Verfügbarkeit prüfen

Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry

Clinical and experimental rheumatology, 2017-09, Vol.35 (5), p.804

2017

Link zum Volltext

Verfügbarkeit prüfen

Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry

Clinical rheumatology, 2021-10, Vol.40 (10), p.4039-4047

2021

Link zum Volltext

Verfügbarkeit prüfen

Serious infections during anti-TNFα treatment in rheumatoid arthritis patients

Autoimmunity reviews, 2009-01, Vol.8 (3), p.266-273

2009

Link zum Volltext

Verfügbarkeit prüfen

Determining the PASS cut-off points for the FIQR, FASmod and PSD in patients with fibromyalgia: a registry-based study

Clinical and experimental rheumatology, 2023-06, Vol.41 (6), p.1275

2023

Link zum Volltext

Verfügbarkeit prüfen

Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA

Joint, bone, spine : revue du rhumatisme, 2016-12, Vol.83 (6), p.721-725

2016

Link zum Volltext

Verfügbarkeit prüfen

Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal

Autoimmunity reviews, 2009-01, Vol.8 (3), p.274-280

2009

Link zum Volltext

Verfügbarkeit prüfen

Switching rheumatoid arthritis treatments: An update

Autoimmunity reviews, 2011-05, Vol.10 (7), p.397-403

2011

Link zum Volltext

Verfügbarkeit prüfen

Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs

Joint, bone, spine : revue du rhumatisme, 2018-07, Vol.85 (4), p.455-459

2018

Link zum Volltext

Verfügbarkeit prüfen

Tumour necrosis factor antagonist therapy and cancer development: Analysis of the LORHEN registry

Autoimmunity reviews, 2010-01, Vol.9 (3), p.175-180

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 94

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(83)
Mit Volltextzugriff
(80)

Publikationsform

Artikel
(93)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(65)
Life Sciences & Biomedicine
(60)
Humans
(49)
Male
(35)
Female
(34)
Adult
(25)
Middle Aged
(24)
Rheumatology
(23)
Aged
(21)
Rheumatoid Arthritis
(21)
Arthritis, Rheumatoid - Drug Therapy
(20)
Italy
(18)
Immunology
(16)
Treatment Outcome
(16)
Antirheumatic Agents - Therapeutic Use
(15)
Registries
(14)
Tumor Necrosis Factor-Alpha - Antagonists & Inhibitors
(13)
Etanercept
(12)
Biological And Medical Sciences
(11)
Infliximab
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry

Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis

Two‐year persistence of golimumab as second‐line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real‐life data from the LORHEN registry

Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry

Analisi di budget impact del biosimilare di etanercept: lo scenario italiano

Factors predicting early discontinuation of methotrexate as a first-line treatment for rheumatoid arthritis in Italy: Results from the GISEA registry

COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study

Obesity and reduction of the response rate to anti–tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine

Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study

TNF-α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry

The measurement of fibromyalgia severity: converting scores between the FIQR, the PSD and the FASmod

Impact of one-year treatment with biotechnological drugs on work ability in patients with rheumatoid arthritis in Italy: a prospective real-life study

Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors

Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs

Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry

Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry

Serious infections during anti-TNFα treatment in rheumatoid arthritis patients

Determining the PASS cut-off points for the FIQR, FASmod and PSD in patients with fibromyalgia: a registry-based study

Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA

Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal

Switching rheumatoid arthritis treatments: An update

Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs

Disease course and obstetric outcomes of pregnancies in juvenile idiopathic arthritis: are there any differences among disease subtypes? A single-centre retrospective study of prospectively followed pregnancies in a dedicated pregnancy clinic

Tumour necrosis factor antagonist therapy and cancer development: Analysis of the LORHEN registry

Suchergebnisse filtern